A Budget for UK science?

26 October 2021

With the UK's autumn Budget in the background, Kath Mackay, director of life sciences at Bruntwood SciTech, considers what funding commitments are required for the UK to be seen as a science superpower.

The news cycle has hit overdrive in the UK ahead of a frenetic couple of weeks that include the autumn Budget, a Comprehensive Spending Review and the COP26 conference in Glasgow.

Rightly, a great deal of focus is on how the UK will deliver on its own "net zero" commitments – especially after the publication of its strategy last week – and we wait for detail on how the government sees businesses and the economy responding to the climate emergency.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK